A study conducted by Dong et al. [98] demonstrated that a high pre-treatment serum ALB–BIL grade was an independent predictor for worse OS and RFS in HCC patients receiving hypofractionated radiation therapy (HFRT) or SBRT combined with immunotherapy with camrelizumab or sintilimab. The gene discussed is ALB; the disease is hepatocellular carcinoma.